- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04070612
National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia. (BIOCEREVANCE)
National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
These autoimmune haematological diseases are rare diseases affecting the child, often very young, and serious and potentially life-threatening. International literature data are scarce, and include individual cases or small series.
They do not allow to determine an optimal therapeutic strategy in case of escape from the first-line treatments. Existing treatments (long-term corticosteroid therapy, immunoglobulins, splenectomy, immunosuppressants, chemotherapies, and more recently anti-CD20 antibodies) are inconsistently effective, and often associated with serious side effects.
The seriousness of these diseases, the therapeutic difficulties, and the absence of a targeted research project in France, led to the implementation of this study.
This study aims to study prospectively the clinical and paraclinical evolution and prognostic factors of autoimmune haemolytic anemias, Evans syndromes and chronic immunological thrombocytopenic purpura of children in France.
Studietyp
Inskrivning (Faktisk)
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age strictly below 18 years of age at initial diagnosis
- Affiliate child or beneficiary of a social security scheme
- Child residing in metropolitan France
- Diagnosis of autoimmune haemolytic anemias, Evans syndrome and / or chronic Immune thrombocytopenic purpura
- Free, informed, written and signed consent
Exclusion Criteria:
- Diagnosis of constitutional haemolytic anemia
- Diagnosis of platelet constitutional disease
Studieplan
Hur är studien utformad?
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
children with autoimmune haemolytic anemia
A blood sample of 2 times 2 to 5 ml additional maximum
|
A blood sample of 2 times 2 to 5 ml additional maximum
|
Children with Evans syndrome
A blood sample of 2 times 2 to 5 ml additional maximum
|
A blood sample of 2 times 2 to 5 ml additional maximum
|
Children with Immune thrombocytopenic purpura
A blood sample of 2 times 2 to 5 ml additional maximum
|
A blood sample of 2 times 2 to 5 ml additional maximum
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Complete sustainable remission (yes/no) for children with autoimmune haemolytic anemias
Tidsram: At the screening
|
Absence of clinical signs of anemia (grade 0) And Hemoglobin > 11 g / dl And reticulocytes <120,000 / mm3 And haptoglobin> 10 mg / dl And bilirubin <10 mg / l or 17 μmol / l And no specific treatment for at least 12 months
|
At the screening
|
complete remission (yes/no) for children with autoimmune haemolytic anemias
Tidsram: At the screening
|
Absence of clinical signs of anemia (grade 0) And Hemoglobin> 11 g / dl And reticulocytes <120,000 / mm3 Regardless of the level of haptoglobin or bilirubin And specific treatment in progress or interrupted for less than 12 months
|
At the screening
|
partial remission (yes/no) for children with autoimmune haemolytic anemias
Tidsram: At the screening
|
Clinical Signs of Anemia (Grade 1 or 2) Or Hemoglobin from 7 to 11 g / dl Or reticulocytes> 120,000 / mm3 Regardless of the level of haptoglobin or bilirubin
|
At the screening
|
no response (yes/no) for children with autoimmune haemolytic anemias
Tidsram: At the screening
|
Clinical Signs of Severe Anemia (Grade 3 or More) Or Hemoglobin <7 g / dl
|
At the screening
|
deceased patient (yes/no) for children with autoimmune haemolytic anemias
Tidsram: At the screening
|
Death yes/no
|
At the screening
|
Complete sustainable remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tidsram: At the screening
|
Absence of clinical signs of haemorrhage (grade 0) And platelets> 100,000 / mm3 And no specific treatment for at least 12 months
|
At the screening
|
complete remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tidsram: At the screening
|
Absence of clinical signs of haemorrhage (grade 0) And platelets> 100,000 / mm3 And specific treatment in progress or interrupted for less than 12 months
|
At the screening
|
partial remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tidsram: At the screening
|
Clinical Signs of Hemorrhage (Grade 1 or 2) Or platelets between 30,000 and 100,000 / mm3
|
At the screening
|
no response (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tidsram: At the screening
|
Clinical Signs of Severe Hemorrhage (Grade 3 or Greater) Or Platelets <30,000 / mm3
|
At the screening
|
deceased patient (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tidsram: At the screening
|
Death yes/no
|
At the screening
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Yves PEREL, Pr, Bordeaux University Hsopital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Immunsystemets sjukdomar
- Autoimmuna sjukdomar
- Hematologiska sjukdomar
- Blödning
- Hemorragiska störningar
- Anemi
- Blodkoagulationsstörningar
- Hudmanifestationer
- Trombocytopeni
- Blodplättssjukdomar
- Trombotiska mikroangiopatier
- Purpura
- Purpura, trombocytopenisk
- Purpura, Trombocytopenisk, Idiopatisk
- Anemi, hemolytisk
- Anemi, hemolytisk, autoimmun
Andra studie-ID-nummer
- CHUBX 2005/18
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Cytopeni
-
Children's Hospital Medical Center, CincinnatiAvslutadAllogen stamcellstransplantation | Refraktär autoimmun cytopeni(er)Förenta staterna
-
Washington University School of MedicineBristol-Myers Squibb; Damon Runyon Cancer Research FoundationHar inte rekryterat ännuKlonal cytopeni av obestämd betydelse | CCUS klonal cytopeni av obestämd betydelseFörenta staterna
-
Memorial Sloan Kettering Cancer CenterRekryteringKlonal cytopeni av obestämd betydelse | CCUS klonal cytopeni av obestämd betydelseFörenta staterna
-
Uma BorateRekryteringKlonal cytopeni av obestämd betydelseFörenta staterna
-
Washington University School of MedicineGateway for Cancer Research; Servier Hellas Pharmaceuticals Ltd.RekryteringKlonal cytopeni av obestämd betydelseFörenta staterna
-
National Heart, Lung, and Blood Institute (NHLBI)RekryteringKlonal cytopeni av obestämd betydelse | Klonal hematopoiesis av obestämd potentialFörenta staterna
-
National Institute of Allergy and Infectious Diseases...IndragenCTLA4 Haploinsufficens | Kronisk cytopeniFörenta staterna
-
National Institutes of Health Clinical Center (CC)AvslutadTrombocytopeni | TrombocyttransfusionsmotståndskraftFörenta staterna
-
National Institutes of Health Clinical Center (CC)Rekrytering
-
M.D. Anderson Cancer CenterSobi, Inc.Har inte rekryterat ännuCytopeniFörenta staterna
Kliniska prövningar på Blood sample
-
Hillel Yaffe Medical CenterOkänd
-
ExThera Medical Europe BVExThera Medical Corporation; Vivantes Clinic NeuköllnRekryteringBlodströmsinfektionFrankrike, Tyskland, Nederländerna, Österrike, Belgien, Italien, Polen, Spanien, Storbritannien
-
Ascensia Diabetes CareAvslutad
-
InSightecFocused Ultrasound FoundationRekrytering
-
University of Southern CaliforniaStanford UniversityAvslutad
-
Stanford UniversityRekryteringKärlsjukdomar | Stroke | Hypertoni | TIAFörenta staterna
-
InSightecRekryteringAlzheimers sjukdomFörenta staterna
-
Helios Klinik Gotha/OhrdrufHelios Klinikum ErfurtHar inte rekryterat ännu
-
Mayo ClinicAvslutad
-
Lauren EricksonAmerican College of Sports MedicineAvslutadPatellofemoralt syndromFörenta staterna